MEI Pharma, Inc. (MEIP)

Oncology Corporate Profile

Stock Performance

1.4400
0.0100

HQ Location

11975 El Camino Real, Suite 101
San Diego, CA 92130

Company Description

MEI Pharma (formerly Marshall Edwards Inc.) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our programs include a potential best-in-class HDAC inhibitor, Pracinostat, and two isoflavone-based drug candidates, ME-143 and ME-344.

Website: http://www.meipharma.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
pracinostat (+ azacitidine)HDAC inhibitor (oral)Acute Myelogenous Leukemia (AML)IIHelsinn
ME-344 (+ bevacizumab)mitochondrial inhibitorBreast cancer (HER2+)II
pracinostat (+ azacitidine)HDAC inhibitor (oral)Myelodysplastic Syndrome (MDS)II
pracinostat (+ ruxolitnib)HDAC inhibitor (oral)MyelofibrosisII
ME-401PI3K Delta InhibitorChronic Lymphocytic Leukemia (CLL)I
ME-401P13K delta inhibitorFollicular LymphomaI
phenoxodiolNADH oxidase inhibitorVarious cancer typesINovogen
ME-143NADH oxidase inhibitorVarious cancer typesI
PWT143P13K delta inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.meipharma.com/

Recent News Headlines

7/20/2017 06:18 pm

7/20/2017 06:18 pm

7/20/2017 06:18 pm

7/20/2017 06:18 pm

7/20/2017 06:18 pm

7/7/2017 06:18 am

7/7/2017 06:18 am

7/7/2017 06:18 am

7/7/2017 06:18 am

7/7/2017 06:18 am

7/3/2017 06:18 am

7/3/2017 06:18 am

7/3/2017 06:18 am

7/3/2017 06:18 am

7/3/2017 06:18 am

6/29/2017 06:19 am

6/29/2017 06:19 am

6/29/2017 06:19 am

6/29/2017 06:19 am

6/22/2017 06:19 am

6/20/2017 06:19 am

6/16/2017 12:22 pm

6/16/2017 12:22 pm

6/16/2017 06:19 am

6/14/2017 06:19 am